PolyPid Secures $30M Upfront in $320M+ D-PLEX 100 Deal with Azurity
PYPD sits 56% above its 52-week low of $3.06.
Summary
PolyPid granted Azurity exclusive U.S. and Canadian rights to D-PLEX 100 in a deal worth over $320 million in potential milestones, including $30 million in upfront and near-term payments, plus tiered royalties. The partnership funds label expansion and sets the stage for a Q1 2027 commercial launch.
Key Events · M&A and Partnerships · PYPD
-
Exclusive D-PLEX 100 Partnership Signed
PolyPid entered an exclusive license and supply agreement with Azurity Pharmaceuticals for D-PLEX 100 in the U.S. and Canada, covering all abdominal SSI indications and potential label expansions.
-
$30M Upfront and Near-Term Cash
Azurity will pay $15 million upfront and an additional $15 million upon FDA acceptance of the D-PLEX 100 NDA, expected in August 2026.
-
Up to $300M in Milestones Plus Royalties
PolyPid is eligible for up to approximately $300 million in regulatory, development, and sales milestones, plus tiered royalties from mid-teen to mid-twenties percentages on net sales.
-
Azurity Funds Label Expansion
Azurity will fund clinical development for potential label expansion beyond abdominal SSI, while PolyPid retains global rights outside the U.S. and Canada and all manufacturing.
Analysis · PYPD · Industrial Applications And Services
PolyPid has locked in a commercialization partner for its lead asset D-PLEX 100 in the U.S. and Canada, transforming from a development-stage biotech to a revenue-ready company. The deal brings $30 million in immediate and near-term cash — $15 million upfront and another $15 million upon FDA acceptance of the NDA, expected next month — plus up to $300 million in milestones and tiered royalties from mid-teens to mid-twenties percent. Azurity will also fund label-expansion studies, while PolyPid retains manufacturing and ex-North America rights. This partnership de-risks the commercial launch, provides non-dilutive capital, and validates the platform ahead of the targeted Q1 2027 U.S. launch.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYPD was trading at $4.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $98.3M. The 52-week trading range was $3.06 to $5.73. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.